Marty Makary's sudden departure from the Food and Drug Administration removes a polarizing figure but leaves the agency facing deeper institutional turmoil and uncertain leadership ahead.
Trump confirmed Makary's exit on Tuesday, describing the Johns Hopkins physician as "a great guy" who was "having some difficulty." The president did not specify whether Makary resigned or was forced out, but the removal follows complaints about Makary's unwillingness to align with certain White House priorities and investor frustrations over unpredictable regulatory decisions that blocked some pharmaceutical candidates.
Kyle Diamantas, a Florida lawyer and Trump Jr. associate who previously headed the FDA's food center, will serve as interim leader. Observers have noted his legal and regulatory credentials, though his appointment signals continued political involvement in the agency's operations.
The timing creates real complications for the Senate. Lawmakers must confirm a new FDA commissioner while simultaneously handling Trump nominees for CDC director and surgeon general. The FDA also has other vacant leadership posts, including directors overseeing drug and biologics centers. Filling all these positions will strain Senate bandwidth, and political headwinds could delay a formal nomination.
Potential successors being discussed include Stephen Hahn, who served as FDA commissioner during Trump's first term, and Brett Giroir, who acted as commissioner briefly. Both represent more establishment options compared to Makary's tenure.
Makary's 13 months in the role were marked by constant upheaval and competing pressures. He resisted efforts to advance Trump's vaping agenda, a move seen as critical to appealing to younger MAGA voters. He also dealt with internal drama involving Vinay Prasad, a former top vaccine regulator whose hiring sparked controversy.
Industry groups remain divided on what comes next. Some welcomed Makary's independence and willingness to push back, including Senate Democrats like Dick Durbin of Illinois, who praised his refusal to simply follow White House orders. But investors and some in the pharmaceutical world criticized the regulatory uncertainty his tenure created. John Crowley, CEO of the biotech trade group BIO, called for "strong, stable and science-driven leadership" to replace the constant churn.
Finding a successor acceptable to both the White House and industry may prove difficult. The agency's credibility has eroded after sweeping DOGE layoffs and the leadership chaos that followed. Any nominee will face scrutiny from Senate health committee chairman Bill Cassidy, who is himself fighting a Trump-endorsed primary challenger this weekend, adding political complexity to the confirmation process.
The broader issue haunting the FDA is whether the next commissioner will continue Makary's push to streamline clinical trials and ease regulatory burdens, or reverse course under different White House pressure. That uncertainty is exactly what the agency's supporters say it cannot afford.
Author James Rodriguez: "Makary's exit shows the FDA has become just another political prize to squabble over, not a place to build policy that lasts."
Comments